Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03WRJ
|
|||
| Former ID |
DNCL002881
|
|||
| Drug Name |
Lisofylline
|
|||
| Synonyms |
LISOFYLLINE; (R)-Lisofylline; 100324-81-0; CT-1501R; ProTec; Lisophylline; NSMXQKNUPPXBRG-SECBINFHSA-N; (R)-Lisophylline; 3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; UNII-L1F2Q2X956; 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione; L1F2Q2X956; ProTec (TN); AC1L9UOZ; Lisofylline (USAN/INN); CHEMBL1411; SCHEMBL39131; GTPL9225; DTXSID7058709; CTK8E6838; CT1501R; MolPort-005-943-169; ZINC1887263; LSF; 1836AH; AKOS025394050; SB18959; DB12406; NCGC00186630-01; FT-0670822
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 2 | [1] | |
| Company |
DiaKine Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H20N4O3
|
|||
| Canonical SMILES |
CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
|
|||
| InChI |
1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
|
|||
| InChIKey |
NSMXQKNUPPXBRG-SECBINFHSA-N
|
|||
| CAS Number |
CAS 100324-81-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:143527
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00464555) Strategies to Improve Islet Survival. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.